Source: Entheon Biomedical Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Entheon Biomedical Corp. (ENBI) has closed the sale of its Phase 1 DMT Study to Cybin IRL Limited for C$1,000,000
  • The DMT Study is being conducted on 50 volunteers at the Centre for Human Drug Research in the Netherlands
  • Entheon has entered into a 12-month consulting services agreement and has signed a data license agreement with Cybin IRL
  • Entheon is a biotechnology research and development company developing DMT-based psychedelic therapeutic products
  • Entheon Biomedical Corp. (ENBI) opened trading at C$0.05

Entheon Biomedical Corp. (ENBI) has closed the sale of its Phase 1 DMT study to Cybin IRL Limited for C$1,000,000.

Cybin IRL has assumed all accrued liabilities and accounts payable associated with the previously announced DMT study.

The DMT Study is being conducted in the Netherlands at the Centre for Human Drug Research, a leading independent foundation specializing in innovative early-stage clinical drug research, in 50 healthy volunteers who smoke (cigarettes/nicotine users).

Entheon has entered into a consulting services agreement with the Cybin IRL for a period of 12 months. Entheon has also signed a data license agreement with Cybin, allowing the company access to certain clinical trial data to support its Entheon IQ program.

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective DMT-based psychedelic therapeutic products to treat addiction and substance use disorders.

Entheon Biomedical Corp. (ENBI) opened trading at C$0.05.

More From The Market Herald

" Red Light Holland (CSE:TRIP) utilizing 3D movement data for psychedelic therapy

Red Light Holland (TRIP) subsidiary Radix Motion has received an International Preliminary Report on Patentability on the patent application filed in 2020. ...

" Algernon (CSE:AGN) receives FDA Orphan Drug Designation for Ifenprodil to treat Idiopathic Pulmonary Fibrosis

Algernon Pharmaceuticals (AGN) has been granted Orphan Drug Designation (ODD) for Ifenprodil to treat Idiopathic Pulmonary Fibrosis (IPF).

" Lobe Sciences (CSE:LOBE) advances clinical development plans for its proprietary psilocin product

Lobe Sciences (LOBE) released an update for its clinical development plans for its proprietary Psilocin-based compound L-130.